At the 2017 Conference on Retroviruses and Opportunistic Infections (CROI), trends in the HIV epidemic were highlighted, with decreasing HIV incidence reported across several countries, although key groups remain underdiagnosed and undertreated. In the United States, men who have sex with men (MSM) continue to comprise the largest number of new and undiagnosed HIV infections, with rising incide...

It has not been well elucidated whether patients with measles who have undergone postexposure prophylaxis (PEP) exhibit milder clinical symptoms than would be expected in the absence of PEP. In the present study, we compared the severity of measles of patients who had undergone incidental PEP to those of patients who had not received such prophylaxis. An outbreak of measles occurred among the p...

To the Editor: The New York State Department of Health (NYSDOH) assessed the effect of terrestrial rabies on human postexposure prophylaxis (PEP) during the first 10-year period of computerized reporting (1993–2002) (1). We assessed the effect of bat rabies during the same period, when guidelines for PEP were changing (2). NYSDOH developed local health department and public education programs t...

BACKGROUND Infection with Human Immunodeficiency Virus is a serious public health problem costing the lives of many people including health workers. Hence, Ethiopia has developed guideline on the prevention of infection in health institutions in July 2004 and also employed the use of post exposure prophylaxis since the implementation of free antiretroviral in January 2005. However in the countr...

context crimean-congo hemorrhagic fever (cchf) is a tick-borne viral disease with a mortality rate of 30% to 80% and reported from more than 30 countries in asia, africa, south-eastern europe, and the middle east. it is a zoonotic viral disease and an important health problem. in endemic areas, livestock handlers, livestock market workers, skin processors, veterinary staff, farmers, and healthc...

In 2012, the US Food and Drug Administration (FDA) approved Truvada to be used as PrEP by HIV negative people who are at high risk of sexually acquired HIV infection. The US Centre for Disease Control has since developed guidelines and recommended PrEP be used by people at high risk of HIV acquisition via sexual transmission or injection drug use (http://www.cdc.gov/hiv/prevention/research/prep/).